This bill requires the University of Massachusetts to submit an annual report detailing the activities of its MassBiologics laboratories, as mandated by Chapter 75, Section 43(f). The report, which is due within ninety days after the end of the fiscal year, includes information on patents, licensing agreements, revenues, expenditures, and the status of existing collaborations. The current report covers Fiscal Year 2026, marking the twenty-ninth year of compliance with this requirement since the transition of the biologic laboratories from the Department of Public Health to the University of Massachusetts.

The report outlines financial details such as total revenues of approximately $19.9 million and expenditures of about $40.5 million for FY26, resulting in a net decrease of over $20 million. It also discusses the establishment and composition of the MassBiologics Advisory Board, which includes representatives from the Department of Public Health and the University, aimed at advising on the operation of the biologic laboratories. The report indicates ongoing efforts to develop a future business plan focused on biologics in the gene therapy space, reflecting the specialized expertise required for this area.